Tag: DAPT
-
COP-INH Score: A New Metric for Predicting Post-PCI Outcomes in ACS Patients
Understanding the Challenge: Platelet Reactivity After PCI Dual antiplatelet therapy (DAPT), typically aspirin plus a P2Y12 receptor antagonist, is standard care after percutaneous coronary intervention (PCI) with drug-eluting stents. While this regimen reduces stent thrombosis and major adverse cardiac events (MACE), patient responses vary. High residual platelet reactivity (HRPR) after clopidogrel therapy has been linked…
-
Shorter Dual Antiplatelet Therapy Benefits for Myocardial Infarction Patients
Recent findings have cast a new light on dual antiplatelet therapy (DAPT) in the context of myocardial infarction (MI). For years, the standard protocol for post-MI management has included a prolonged duration of dual antiplatelet therapy—typically around 12 months. However, emerging evidence suggests that a shorter duration of therapy, specifically three months, may offer significant…